A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)
Clinical trial NCT03751007 · COMPLETED
Trial details
- NCT number
- NCT03751007
- Sponsor
- Precigen Actobio T1D, LLC
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-24
- Primary completion
- 2021-10-13
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.